RxDoctor Payments Data

Kenneth Buczynski, MD

Family Medicine · Oakland, MDNPI 1790704914

Payments from drug & device makers

$1,859in general payments, 2019–2025

Across 104 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$352
  • Novo Nordisk$264
  • Lilly USA, LLC$208
  • Merck$125
  • Astellas Pharma US Inc$122
  • Pfizer$114
  • plus $673 from 16 others

What the payments were for

  • Food & beverage$1,83399%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,859 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$145,914
Medicare patients
575
Services billed
2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$97,084
XareltoRivaroxaban32$53,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$40,012
FarxigaDapagliflozin Propanediol25$35,199
TrulicityDulaglutide15$33,566
JardianceEmpagliflozin28$29,509
RybelsusSemaglutide12$24,172
LinzessLinaclotide16$22,104
EntrestoSacubitril/Valsartan25$20,336
Tresiba Flextouch U-200Insulin Degludec13$14,614
ShingrixVaricella-Zoster Ge/As01b/Pf57$12,680
Atrovent HfaIpratropium Bromide11$5,205
Novolog FlexpenInsulin Aspart21$5,032
SymbicortBudesonide/Formoterol Fumarate15$3,605
Humalog Kwikpen U-100Insulin Lispro12$3,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$97,084100 claims
Johnson & JohnsonXarelto$37$53,74732 claims
GSKTrelegy Ellipta, Shingrix$60$52,69194 claims
AstraZenecaFarxiga, Symbicort$352$38,80440 claims
Lilly USA, LLCTrulicity$208$33,56615 claims
Boehringer IngelheimJardiance$96$29,50928 claims
Novo NordiskRybelsus$264$24,17212 claims
AbbVieLinzess$95$22,10416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Oakland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →